CAMPBELLVILLE, ON, June 4 /CNW/ - NIR Diagnostics Inc. (TSX Venture: NID), an innovator in the development of in-vitro and in-vivo medical diagnostic devices today announced that it has successfully completed internal testing of its in-vivo light-based platform for an application that monitors levels of omega-6 and omega-3 fatty acids non-invasively. The portable OmegaNIR(TM) device has been developed on the Company’s VisionNIR(TM) platform which allows a user to monitor blood and tissue with the use of near-infrared light. This eliminates the need to secure a blood sample for expensive and time consuming laboratory tests. NIR Diagnostics plans to initiate live patient testing of cardiac patients at cardiac clinics in Los Angeles County, California.
